A comprehensive study on hemostasis in CAPD patients treated with erythropoietin

Peritoneal Dialysis International

Volumn 22, Issue 5, 2002, Pages 582-592

  Malyszko, Jolanta ^a   Suchowierska, Ewa ^a   Malyszko, Jacek S ^a   Mysliweic, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Coagulation; Endothelium; Fibrinolysis; Hemostasis; Platelet aggregation

Indexed keywords

ANTIPLASMIN; ARACHIDONIC ACID; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; COLLAGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FOLIC ACID; IRON; LIPOPROTEIN A; PADGEM PROTEIN; PERITONEAL DIALYSIS FLUID; PLASMIN; PROTHROMBIN; RECOMBINANT ERYTHROPOIETIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING; CELL DAMAGE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HOSPITAL DEPARTMENT; HUMAN; INTERNAL MEDICINE; KIDNEY FAILURE; MALE; MEDICAL RESEARCH; NEPHROLOGY; POLAND; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

EID: 0036755731     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080202200509     Document Type: Article

References (48)

1. Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997; 75:125-39.
2. Locatelli F, Del Vecchio L, Manzoni C. Morbidity and mortality on maintenance hemodialysis. Nephron 1998; 80:380-400.
3. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78:386-91.
4. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273:27176-81.
5. Bajzar L, Nesheim ME, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273:2793-8.
6. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost 1997; 77:408-23.
7. Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic: syndrome. Kidney Int 1985; 28:429-33.
8. Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostatic disturbances between patients on CAPD and hemodialysis. Perit Dial Int 2001; 21:158-65.
9. Kario K, Matsuo T, Yamada T, Matsuo M. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994; 71:275-9.
10. Taylor JE, Belch JJF, McLarem M, Henderson IS, Stewart WK. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kidney Int 1993; 44:182-90.
11. Wirtz JJM, van Esser JWJ, Hamulyak K, Leunissen KML, van Hoof JP. The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients. Clin Nephrol 1992; 38:277-82.
12. Huraib S, Al-Momen AK, Gader AMA, Mitwalli A, Sulimani F, Abu-Aisha H. Effect of recombinant human erythropoietin on the hemostatic system in chronic hemodialysis patients. Clin Nephrol 1991; 36: 252-7.
13. Malyszko J, Malyszko JS, Borawski J, Rydzewski A, Kalinowski M, Azzadin A, et al. A study of platelet function, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 1995; 77:133-44.
14. Takayama K. Changes in endothelial vasoactive substances and blood coagulation and fibrinolysis functions under recombinant human erythropoietin therapy in hemodialysis patients. Nippon Jinzo Gakkai Shi 1993; 35:177-88.
15. Malyszko JS, Malyszko J, Pawlak D, Pawlak K, Buczko W, Mysliwiec M. An importance of serotonergic mechanism in thrombotic complications in rHuEPO-treated patients. Nephron 2000; 84:305-11.
16. Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 2000; 97:6930-2.
17. Malyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y, et al. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 1994; 75:569-76.
18. Wilsoncroft PS, Lofts FJ, Griffiths RJ, Moore PK. The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitro. J Pharm Pharmacol 1985; 37:139-41.
19. Malyszko J, Malyszko JS, Mysliwiec M, Takada Y, Takada A. Cyclosporine and FK 506 affect platelet function in vitro. Platelets 1995; 6:366-70.
20. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9.
21. Kowalski E, Kopec M, Niewiarowski S. An evaluation of the euglobulin method for determination of fibrinolysis. J Clin Pathol 1959; 12:215-21.
22. Lai KN, Yin JA, Li PKT, Yuen PMP, Lui SF. Effect of subcutaneous administration of recombinant erythropoietin on plasma protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis. Int J Artif Organs 1992; 15:264-8.
23. Roger SD, Piper J, Tucker B, Raine AEG, Baker LRI, Kovacs IB. Enhanced platelet reactivity with erythropoietin but not following transfusion in dialysis patients. Nephrol Dial Transplant 1993; 8:213-17.
24. Taylor JE, Henderson IS, Stewart WK, Belch JJF. Platelet aggregation in erythropoietin treated dialysis patients. Platelets 1992; 3:47-52.
25. Turi S, Soos J, Torday C, Bersczki C, Havass Z. The effect of erythropoietin on platelet function in uremic children on hemodialysis. Pediatr Nephrol 1994; 8:727-32.
26. Aunsholt NA, Steffensen G, Ahlbom G. Influence of recombinant human erythropoietin on platelet function and coagulation factors. Blood Purif 1992; 10: 248-53.
27. Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996; 27:848-54.
28. Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1997; 76:56-61.
29. Sokunbi DOB, Wadhwa NK, Suh H. Vascular disease outcome and thrombocytosis in diabetic and nondiabetic end-stage renal disease patients on peritoneal dialysis. Adv Perit Dial 1994; 10:77-80.
30. Aguilera A, Selgas R, Ruiz-Caravaca ML, Bajo MA, Cuesta MV, Plaza MA, et al. Effects of recombinant human erythropoietin on functional and injury endothelial markers in peritoneal dialysis patients. Perit Dial Int 1999; 19(Suppl 2):S161-6.
31. Malyszko J, Mazerska M, Malyszko JS, Pawlak K, Azzadin A, Mysliwiec M, et al. Serotonergic mechanisms are involved in the hemostatic action of erythropoietin in uremic patients. Int J Clin Lab Res 1993; 23:42-4.
32. Malyszko JS, Malyszko J, Pawlak K, Mysliwiec M. Erythropoietin and platelet aggregation in vivo and in vitro. Int J Lab Clin Res 1996; 26:199-202.
33. Kuriyama S, Hopp L, Yoshida H, Hikita M, Tomonari H, Hashimoto T, et al. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am J Hypertens 1996; 9:426-31.
34. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101:880-6.
35. Wagner DD. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin. Thromb Haemost 1993; 74:626-30.
36. Blann AD, Lip GYH. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 1997; 128:135-8.
37. Ishiwata N, Takio K, Katayama M, Watanabe K, Titani K, Ikeda Y, et al. Alternatively spliced isoform of P-selectin is present in vivo as soluble molecule. J Biol Chem 1994; 38:23708-15.
38. Gearing AJH, Hemingway I, Piggott R, Hughes J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules. E-selectin, ICAM-1 and VCAM-1: pathological significance. Ann NY Acad Sci 1992; 667:324-31.
39. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74:90-3.
40. Cotran RS, Pober JS. Effects of cytokines on vascular endothelium: their role in vascular and immune injury. Kidney Int 1989; 35:969-75.
41. Cotran RS, Pober JS. Cytokine-endothelial interactions in inflammation, immunity, and vascular injury. J Am Soc Nephrol 1990; 1:225-35.
42. Malyszko J, Zbroch E, Wolczynski S, Mysliwiec M. Selected parameters of bone metabolism in hemodialyzed and peritoneally dialyzed patients [in Polish]. Przegl Lek 2001; 57:711-13.
43. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95:2855-9.
44. Kluft C, Meijer P, Biasucci LM, Meo A, Vitrella G, Liuzzo G, et al. Plasma levels of TAFI are elevated in patients with unstable angina pectoris (UAP) compared to stable angina pectoris but show no relationship with outcome of UAP (Abstract). Thromb Haemost 1999; Suppl:A784.
45. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80:829-35.
46. Hryszko T, Malyszko J, Malyszko JS, Brzósko S, Pawlak K, Mysliwiec M. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrol Dial Transplant 2001; 16:1692-6.
47. Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Simvastatin affects TAFI and thrombomodulin in CAPD patients. Thromb Haemost 2001; 86:900-1.
48. Hosaka Y, Takahashi Y, Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma. Thromb Haemost 1998; 79:371-7.